MGMounes Aliyari Ghasabeh

Mounes Aliyari Ghasabeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mounes Aliyari Ghasabeh has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Ihab R. Kamel

    University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado

    9 shared publications
  • Pegah Khoshpouri

    From the Department of Radiology, The Ottawa Hospital, 1053 Carling Ave, Ottawa, ON, Canada K1Y 4E9 (M.L.B.V.); Department of Radiology, University of Washington, Seattle, Wash (P.K.); Department of Radiology, University of Pennsylvania, Philadelphia, Pa (J.K.); Department of Radiology, Yale New Haven Health, Yale University, New Haven, Conn (A.S.); and Department of Radiology, University of Wisconsin, Madison, Wis (P.J.P.).

    5 shared publications
  • Sanaz Ameli

    Russell H. Morgan Department of Radiology and Radiological Sciences

    5 shared publications
  • Pallavi Pandey

    From the Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, 600 N Wolfe St, Room 143, Baltimore, MD 21287

    4 shared publications
  • Ankur Pandey

    From the Russell H. Morgan Department of Radiology and Radiological Sciences (P.P., A.P., Y.L., M.A.G., P.K., S.Z., I.R.K.) and the Departments of Medicine, Division of Gastroenterology and Hepatology (A.M.O.L., M.C., M.S.G.), Pathology (R.H.H., M.S.G.), and Surgery, Division of Surgical Oncology (C.W.), Johns Hopkins University School of Medicine, 600 N Wolfe St, Room 143, Baltimore, MD 21287

    3 shared publications
  • Bita Hazhirkarzar

    Russell H. Morgan Department of Radiology and Radiological Sciences

    2 shared publications

Latest Publications

  • Open Access

    Practical Application of Multivendor MRI‐Based R2* Mapping for Liver Iron Quantification at 1.5 T and 3.0 T

    by Gregory Simchick, Ruiyang Zhao, Qing Yuan, Mounes Aliyari Ghasabeh, Stefan Ruschke, Dimitrios C. Karampinos, David T. Harris, Raphael Do Vale Souza, Ryan J. Mattison, Michael R. Jeng, et al.

    Background: Recent multicenter, multivendor MRI‐based R2* vs. liver iron concentration (LIC) calibrations (i.e., MCMV calibrations) may facilitate broad clinical dissemination of R2*‐based LIC quantification. However, these calibrations are based on a centralized offline R2* reconstruction, and their applicability with vendor‐provided R2* maps is unclear.Purpose: To determine R2* ranges of agreement between the centralized and three MRI vendors' R2* reconstructions.Study Type: Prospective.Subjects: Two hundred and seven subjects (mean age 37.6 ± 19.6 years; 117 male) with known or suspected iron overload from four academic medical centers.Field Strength/Sequence: Standardized multiecho spoiled gradient echo sequence at 1.5 T and 3.0 T for R2* mapping and a multiple spin‐echo sequence at 1.5 T for LIC quantification. MRI vendors: GE Healthcare, Philips Healthcare, and Siemens Healthineers.Assessment: R2* maps were generated using both the centralized and vendor reconstructions, and ranges of agreement were determined. R2*‐LIC linear calibrations were determined for each site, field strength, and reconstruction and compared with the MCMV calibrations.Statistical Tests: Bland–Altman analysis to determine ranges of agreement. Linear regression, analysis of covariance F tests, and Tukey's multiple comparison testing to assess reproducibility of calibrations across sites and vendors. A P value −1 for GE, Philips, and Siemens reconstructions, respectively, at 1.5 T and approximately 700 and 800 s−1 for GE and Philips, respectively, at 3.0 T. Within the R2* ranges of agreement, vendor R2*‐LIC calibrations demonstrated high reproducibility (no significant differences between slopes or intercepts; P ≥ 0.06) and agreed with the MCMV calibrations (overlapping 95% confidence intervals).Data Conclusion: Based on the determined upper limits, R2* measurements obtained from vendor‐provided R2* maps may be reliably and practically used to quantify LIC less than approximately 8–13 mg/g using the MCMV calibrations and similar acquisition parameters as this study.Evidence Level: 1Technical Efficacy: Stage 3


  • Multicenter Reproducibility of Liver Iron Quantification with 1.5-T and 3.0-T MRI

    by Diego Hernando, Ruiyang Zhao, Qing Yuan, Mounes Aliyari Ghasabeh, Stefan Ruschke, Xinran Miao, Dimitrios C. Karampinos, Lu Mao, David T. Harris, Ryan J. Mattison, et al.

    MRI-based R2* mapping enabled reproducible quantification of liver iron overload across four centers, three vendors, and three field strengths (1.5 T, 2.89 T, and 3.0 T). Background MRI is a standard of care tool to measure liver iron concentration (LIC). Compared with regulatory-approved R2 MRI, R2* MRI has superior speed and is available in most MRI scanners; howe...


  • Can Posttransarterial Chemoembolization Volumetric Oil Deposition on Computed Tomography Predict Treatment Response on Magnetic Resonance Imaging in Leiomyosarcoma Metastases to the Liver?

    by Bita Hazhirkarzar, Mohammadreza Shaghaghi, Azarakhsh Md Baghdadi, Maryam Ghadimi, Mounes Aliyari Ghasabeh, Qingxia Wu, Hao Tang, Pegah Khoshpouri, Sanaz Ameli, Roya R. Habibabadi, et al.

    Objective To predict early tumor response to transarterial chemoembolization (TACE) based on volumetric oil deposition on posttreatment computed tomography (CT) in patients with leiomyosarcoma liver metastases. Methods This retrospective lesion-by-lesion based study included 32 lesions. The volumetric percent enhancing tumor on pre-TACE and 1-month post-TACE venous phase magnetic resonance imaging (MRI), and the percent oil deposition on CT 1 day after TACE were calculated. The predicted post-TACE enhanced percentage was computed by subtracting percent oil deposition from baseline percent enhanced. Results Mean percentage of viable tumor on pre-TACE MRI was 90.6% ± 9.3%. Mean oil deposition was calculated as 51.4% ± 26.2%. Mean percentage of measured residual tumor enhancement 1 month after TACE was 58.3% ± 27%, which correlates with predicted enhancement percentage of 43.9% ± 25.1% (r = 0.72, P < 0.001). A threshold of 35.5% for enhancement reduction was determined to predict tumor response with an accuracy of 78.1%. Conclusion Volumetric oil deposition on CT can predict residual enhancement on post-TACE MRI.


  • Imaging Features of Primary Sclerosing Cholangitis: From Diagnosis to Liver Transplant Follow-up

    by Pegah Khoshpouri, Roya Rezvani Habibabadi, Bita Hazhirkarzar, Sanaz Ameli, Maryam Ghadimi, Mounes Aliyari Ghasabeh, Christine O. Menias, Amy Kim, Zhiping Li, Ihab R. Kamel

    Recognizing the multimodality imaging features of the biliary system and liver parenchyma in primary sclerosing cholangitis can help the radiologist provide an accurate diagnosis, identify a differ... Primary sclerosing cholangitis (PSC) is a chronic progressive inflammatory disease of the bile ducts that leads to multifocal bile duct fibrosis, strictures, cholestasis, liver parenchymal changes,...


  • Follow-up of Incidentally Detected Pancreatic Cystic Neoplasms: Do Baseline MRI and CT Features Predict Cyst Growth?

    by Pallavi Pandey, Ankur Pandey, Yan Luo, Mounes Aliyari Ghasabeh, Pegah Khoshpouri, Sanaz Ameli, Anne Marie O’bRoin-Lennon, Marcia Canto, Ralph H. Hruban, Michael S. Goggins, et al.

    Pancreatic cystic neoplasms 15–25 mm in size were most likely to show growth on follow-up images obtained with CT or MRI; however, very small lesions (<5 mm) showed no interval growth until at leas... Background Incidental detection of pancreatic cystic neoplasm (PCN) has increased. Since a small percentage of PCNs possess malignant potential, management is challenging. The recently revised Amer...


  • Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization

    by Yan Luo, Sanaz Ameli, Ankur Pandey, Pegah Khoshpouri, Mounes Aliyari Ghasabeh, Pallavi Pandey, Zhen Li, Daoyu Hu, Ihab R. Kamel

    To evaluate the accuracy and reproducibility of semi-quantitative visual assessment of hepatic tumor burden (HTB) on MRI and to investigate its prognostic value in predicting overall survival (OS) in neuroendocrine liver metastases (NELMs) treated with transarterial chemoembolization (TACE).


  • Epicardial Fat Distribution Assessed with Cardiac CT in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy

    by Mounes Aliyari Ghasabeh, Anneline S. J. M. Te Riele, Cynthia A. James, H. S. Vincent Chen, Crystal Tichnell, Brittney Murray, John Eng, Brian G. Kral, Harikrishna Tandri, Hugh Calkins, et al.

    The higher amount of epicardial fat in hearts with arrhythmogenic right ventricular dysplasia/cardiomyopathy, particularly surrounding the left ventricle, could provide an indicator for the degree ... Purpose To compare epicardial fat in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) with that in healthy subjects. Materials and Methods In this retrospective stud...


  • Baseline Volumetric Multiparametric MRI: Can It Be Used to Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma Undergoing Transcatheter Arterial Chemoembolization?

    by Ankur Pandey, Pallavi Pandey, Mounes Aliyari Ghasabeh, Manijeh Zarghampour, Pegah Khoshpouri, Sanaz Ameli, Yan Luo, Ihab R. Kamel

    Baseline multiparametric MRI assessment including volumetric apparent diffusion coefficient, percentage viable tumor volume, and viable tumor burden can help predict mortality risk in patients with unresectable intrahepatic cholangiocarcinoma undergoing transcatheter arterial chemoembolization. PurposeTo evaluate whether baseline MRI can help predict survival in patients with unresectable intrahepatic cholangiocarcinoma (ICCA) undergoing transcatheter arterial chemoembolization (TACE).Materials and MethodsThis retrospective study was compliant with HIPAA and approved by the institutional review board. The requirement to obtain informed consent was waived. The study included 111 patients (mean age, 62 years ± 12; range, 29–86 years), with 44 men (mean age, 61 years ± 12; range, 29–81 years) and 67 women (mean age, 63 years ± 12; range, 34–86 years). Patients underwent TACE after baseline MRI, which included contrast-enhanced and diffusion-weighted imaging with apparent diffusion coefficient (ADC) mapping between 2003 and 2016. The single largest tumor was assessed independently by a radiologist for anatomic and functional (viable tumor volume, percentage viable tumor volume [100 × viable tumor volume/whole tumor volume], viable tumor burden [100 × viable tumor volume/whole liver volume], and ADC)...


  • Unresectable Intrahepatic Cholangiocarcinoma: Multiparametric MR Imaging to Predict Patient Survival

    by Ankur Pandey, Pallavi Pandey, Mounes Aliyari Ghasabeh, Farnaz Najmi Varzaneh, Nannan Shao, Pegah Khoshpouri, Manijeh Zarghampour, Daniel Fadaei Fouladi, Robert Liddell, Ihab R. Kamel

    Purpose: To determine the performance of magnetic resonance (MR) imaging-based tumor metrics for evaluation of response to transarterial chemoembolization (TACE) in patients with unresectable intrahepatic cholangiocarcinoma (ICCA). Materials and Methods: Ninety-four patients with unresectable ICCA underwent baseline and follow-up MR imaging after TACE and were followed up until death or end of study duration. Lesions were analyzed for anatomic (Response Evaluation Criteria in Solid Tumors [RECIST] and tumor volume) and functional (viable tumor volume, viable tumor burden, and apparent diffusion coefficient [ADC]) volumetric MR parameters by using semiautomatic software. Response was assessed by using changes in viable tumor volume by using modified RECIST (mRECIST)-derived thresholds (three-dimensional mRECIST), viable tumor burden, and ADC. Overall survival was the primary endpoint. Cox-regression and Kaplan-Meier survival analysis were used. Results: Tumor volume did not change after TACE (P=.07) whereas RECIST diameter showed a small change (22.6%; P=.02). There was an increase in ADC (20.7%) and a decrease in viable tumor volume (229.3%) and viable tumor burden (229.1%; P<.001 for all). Higher overall survival was noted among responders by using thresholds of 25% increase in ADC, 66% decrease in viable tumor volume, and 50% decrease in viable tumor burden (log-rank test, P<.05). Hazard ratio for nonresponders by using ADC, three-dimensional mRECIST, and viable tumor burden at multivariable analysis was 2.9 (P=.004), 4.1 (P =.009), and 4.0 (P=.002), respectively. Survival differences were noted for patients who showed response by using all three parameters (ADC, three-dimensional mRECIST, and viable tumor burden) versus those who showed response by using either one or two of these parameters versus those who showed no response (P<.001). Conclusion: Changes in volumetric ADC, viable tumor volume, and viable tumor burden at MR imaging provide prognostic information among patients with unresectable ICCA who undergo TACE. (c) RSNA, 2018